Literature DB >> 24090476

Insights into soluble guanylyl cyclase activation derived from improved heme-mimetics.

Margarete von Wantoch Rekowski1, Vijay Kumar2, Focco van den Akker2, Athanassios Giannis1, Andreas Papapetropoulos3, Zongmin Zhou3,4, Johann Moschner1, Antonia Marazioti3, Marina Bantzi1, Georgios A Spyroulias3.   

Abstract

Recently, the structure of BAY 58-2667 bound to the Nostoc sp. H-NOX domain was published. On the basis of this structural information, we designed BAY 58-2667 derivatives and tested their effects on soluble guanylyl cyclase (sGC) activity. Derivative 20 activated sGC 4.8-fold more than BAY 58-2667. Co-crystallization of 20 with the Ns H-NOX domain revealed that the increased conformational distortion at the C-terminal region of αF helix containing 110-114 residues contributes to the higher activation triggered by 20.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24090476      PMCID: PMC3902542          DOI: 10.1021/jm400539d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

Review 1.  Guanylyl cyclases and signaling by cyclic GMP.

Authors:  K A Lucas; G M Pitari; S Kazerounian; I Ruiz-Stewart; J Park; S Schulz; K P Chepenik; S A Waldman
Journal:  Pharmacol Rev       Date:  2000-09       Impact factor: 25.468

Review 2.  Regulation of nitric oxide-sensitive guanylyl cyclase.

Authors:  Andreas Friebe; Doris Koesling
Journal:  Circ Res       Date:  2003-07-25       Impact factor: 17.367

3.  Expression and characterization of the catalytic domains of soluble guanylate cyclase: interaction with the heme domain.

Authors:  Jonathan A Winger; Michael A Marletta
Journal:  Biochemistry       Date:  2005-03-15       Impact factor: 3.162

4.  Electrochemically assisted Heck reactions.

Authors:  Jun Tian; Kevin D Moeller
Journal:  Org Lett       Date:  2005-11-24       Impact factor: 6.005

Review 5.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 6.  Soluble guanylate cyclase: the forgotten sibling.

Authors:  A J Hobbs
Journal:  Trends Pharmacol Sci       Date:  1997-12       Impact factor: 14.819

Review 7.  The nitrovasodilators. New ideas about old drugs.

Authors:  D G Harrison; J N Bates
Journal:  Circulation       Date:  1993-05       Impact factor: 29.690

8.  Diazonamide support studies: stereoselective formation of the C10 chiral center in both the CDEFG and AEFG fragments.

Authors:  Jinzhen Lin; Brian S Gerstenberger; Nhu Y T Stessman; Joseph P Konopelski
Journal:  Org Lett       Date:  2008-08-15       Impact factor: 6.005

Review 9.  NO-independent, haem-dependent soluble guanylate cyclase stimulators.

Authors:  Johannes-Peter Stasch; Adrian J Hobbs
Journal:  Handb Exp Pharmacol       Date:  2009

10.  Synthesis of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas and evaluation as modulators of the isoforms of nitric oxide synthase.

Authors:  Claire L M Goodyer; Edwin C Chinje; Mohammed Jaffar; Ian J Stratford; Michael D Threadgill
Journal:  Bioorg Med Chem       Date:  2003-09-15       Impact factor: 3.641

View more
  3 in total

Review 1.  Bacterial Haemoprotein Sensors of NO: H-NOX and NosP.

Authors:  Bezalel Bacon; Lisa-Marie Nisbett; Elizabeth Boon
Journal:  Adv Microb Physiol       Date:  2017-03-18       Impact factor: 3.517

2.  Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide.

Authors:  Zongmin Zhou; Emil Martin; Iraida Sharina; Iolanda Esposito; Csaba Szabo; Mariarosaria Bucci; Giuseppe Cirino; Andreas Papapetropoulos
Journal:  Pharmacol Res       Date:  2016-07-01       Impact factor: 7.658

Review 3.  Maturation, inactivation, and recovery mechanisms of soluble guanylyl cyclase.

Authors:  Dennis J Stuehr; Saurav Misra; Yue Dai; Arnab Ghosh
Journal:  J Biol Chem       Date:  2021-01-26       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.